Literature DB >> 25293827

Factors associated with false-positive and false-negative fecal immunochemical test results for colorectal cancer screening.

Martin C S Wong1, Jessica Y L Ching2, Victor C W Chan2, Thomas Y T Lam2, Arthur K C Luk2, Simon S M Ng2, Joseph J Y Sung2.   

Abstract

BACKGROUND: Certain subgroups have higher rates of false fecal immunochemical test (FIT) results, yet few studies have addressed this topic.
OBJECTIVE: To identify demographic factors associated with false-positive and false-negative FIT results in colorectal cancer screening.
DESIGN: Retrospective database review of prospectively collected data.
SETTING: A bowel cancer screening center in Hong Kong invited participants for colorectal cancer screening (2008-2012). PATIENTS: Study participants who underwent both FIT and colonoscopy in the first year (n = 4482) and underwent colonoscopy after negative FIT results for 3 consecutive years (n = 857). MAIN OUTCOME MEASUREMENTS: The diagnostic accuracy and predictive values of FIT according to participant characteristics.
RESULTS: The sensitivity, specificity, positive predictive values, and negative predictive values for advanced neoplasia were 33.1%, 91.9%, 19.0%, and 96.0%, respectively. Participants 66 to 70 years of age had higher sensitivity, whereas older age, smoking, and use of aspirin/nonsteroidal anti-inflammatory drugs were associated with lower specificity. The rates of false-positive and false-negative results were 8.1% and 66.9%, respectively. Older age (66-70 years; adjusted odds ratio [AOR] 1.95; 95% confidence interval [CI], 1.35-2.81; P < .001), smoking (AOR 1.68; 95% CI, 1.08-2.61; P = .020), and the presence of polypoid adenoma (AOR 1.71; 95% CI, 1.14-2.57; P = .009) were associated with false-positive results. Younger participants (AOR for elderly participants 0.31) and the use of aspirin/nonsteroidal anti-inflammatory drugs (AOR 4.44) in participants with 1 FIT with negative results and the absence of high-grade dysplasia (AOR for presence 0.41) were associated with false-negative results. LIMITATIONS: Self-referred participants who received one type of qualitative FIT.
CONCLUSION: These findings could be used to target screening more toward those with a higher risk of false-negative results and those with a lower risk of false-positive results for earlier colonoscopy.
Copyright © 2015 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25293827     DOI: 10.1016/j.gie.2014.08.006

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  11 in total

1.  Where does it FIT? The roles of fecal testing and colonoscopy in colorectal cancer screening.

Authors:  Grace Clarke Hillyer; Alfred I Neugut
Journal:  Cancer       Date:  2015-05-20       Impact factor: 6.860

2.  Diagnostic Accuracy of Fecal Immunochemical Test in Patients at Increased Risk for Colorectal Cancer: A Meta-analysis.

Authors:  Anastasia Katsoula; Paschalis Paschos; Anna-Bettina Haidich; Apostolos Tsapas; Olga Giouleme
Journal:  JAMA Intern Med       Date:  2017-08-01       Impact factor: 21.873

3.  Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.

Authors:  Clasine M de Klerk; Lisanne M Vendrig; Patrick M Bossuyt; Evelien Dekker
Journal:  Am J Gastroenterol       Date:  2018-08-29       Impact factor: 10.864

4.  Nonsteroidal Anti-Inflammatory Drug-Induced Colopathy in a Colorectal Cancer Screening Program.

Authors:  Sanja Borozan; Ljiljana Vuckovic; Brigita Smolovic
Journal:  Med Princ Pract       Date:  2018-10-25       Impact factor: 1.927

5.  Comparative effectiveness of five fecal immunochemical tests using colonoscopy as the gold standard: study protocol.

Authors:  Barcey T Levy; Jeanette M Daly; Yinghui Xu; Seth D Crockett; Richard M Hoffman; Jeffrey D Dawson; Kim Parang; Navkiran K Shokar; Daniel S Reuland; Marc J Zuckerman; Avraham Levin
Journal:  Contemp Clin Trials       Date:  2021-05-08       Impact factor: 2.261

6.  Colorectal Cancer Screening Based on Age and Gender: A Cost-Effectiveness Analysis.

Authors:  Martin C S Wong; Jessica Y L Ching; Victor C W Chan; Thomas Y T Lam; Arthur K C Luk; Sunny H Wong; Siew C Ng; Simon S M Ng; Justin C Y Wu; Francis K L Chan; Joseph J Y Sung
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 7.  Which Fecal Immunochemical Test Should I Choose?

Authors:  Jeanette M Daly; Yinghui Xu; Barcey T Levy
Journal:  J Prim Care Community Health       Date:  2017-04-27

8.  Predictive Modeling of Colonoscopic Findings in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.

Authors:  Jade Law; Anand Rajan; Harry Trieu; John Azizian; Rani Berry; Simon W Beaven; James H Tabibian
Journal:  Dig Dis Sci       Date:  2021-08-04       Impact factor: 3.487

9.  The comparative cost-effectiveness of colorectal cancer screening using faecal immunochemical test vs. colonoscopy.

Authors:  Martin C S Wong; Jessica Y L Ching; Victor C W Chan; Joseph J Y Sung
Journal:  Sci Rep       Date:  2015-09-04       Impact factor: 4.379

10.  Positive predictive values of fecal immunochemical tests used in the STOP CRC pragmatic trial.

Authors:  Carrie M Nielson; Amanda F Petrik; Lorie Jacob; William M Vollmer; Erin M Keast; Jennifer L Schneider; Jennifer S Rivelli; Tanya J Kapka; Richard T Meenan; Rajasekhara R Mummadi; Beverly B Green; Gloria D Coronado
Journal:  Cancer Med       Date:  2018-08-13       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.